NVS

116.61

-0.88%↓

ABT

125.98

+0.48%↑

MDT

92.44

+0.65%↑

ELV.US

289.64

+1.52%↑

VEEV

289.86

-0.17%↓

NVS

116.61

-0.88%↓

ABT

125.98

+0.48%↑

MDT

92.44

+0.65%↑

ELV.US

289.64

+1.52%↑

VEEV

289.86

-0.17%↓

NVS

116.61

-0.88%↓

ABT

125.98

+0.48%↑

MDT

92.44

+0.65%↑

ELV.US

289.64

+1.52%↑

VEEV

289.86

-0.17%↓

NVS

116.61

-0.88%↓

ABT

125.98

+0.48%↑

MDT

92.44

+0.65%↑

ELV.US

289.64

+1.52%↑

VEEV

289.86

-0.17%↓

NVS

116.61

-0.88%↓

ABT

125.98

+0.48%↑

MDT

92.44

+0.65%↑

ELV.US

289.64

+1.52%↑

VEEV

289.86

-0.17%↓

Search

Johnson and Johnson

Open

SectorHealthcare

167.6 -0.9

Overview

Share price change

24h

Current

Min

167.45

Max

169.81

Key metrics

By Trading Economics

Income

7.6B

11B

Sales

1.9B

24B

P/E

Sector Avg

17.579

38.156

EPS

2.77

Dividend yield

3.07

Profit margin

50.24

Employees

138,100

EBITDA

-9.1B

6.5B

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+4.29% upside

Dividends

By Dow Jones

Dividend yield

Sector Avg

3.07%

2.50%

Next Earnings

14 paź 2025

Next Dividend date

9 wrz 2025

Next Ex Dividend date

26 sie 2025

Market Stats

By TradingEconomics

Market Cap

18B

395B

Previous open

168.5

Previous close

167.6

News Sentiment

By Acuity

23%

77%

48 / 375 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Bullish Evidence

Johnson and Johnson Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

16 lip 2025, 16:47 UTC

Earnings

J&J Raises Full-Year Outlook After Beating 2Q Expectations -- Update

16 lip 2025, 18:08 UTC

Market Talk
Earnings

J&J's Orthopedic Decline Likely Hinges on Company-Specific Challenges -- Market Talk

16 lip 2025, 17:27 UTC

Market Talk
Earnings

J&J Expects Medical Devices Sales Boost from Cardiovascular -- Market Talk

16 lip 2025, 17:17 UTC

Market Talk
Earnings

J&J Sees Growth Across Portfolio Offsetting Loss of Stelara -- Market Talk

16 lip 2025, 16:34 UTC

Market Talk
Earnings

J&J Sees Lower Tariff Risk for the Year -- Market Talk

16 lip 2025, 13:27 UTC

Earnings

Johnson & Johnson Beats Earnings Estimates. CFO Says It Can Do Any Deal It Wants. -- Barrons.com

16 lip 2025, 10:32 UTC

Earnings

Johnson & Johnson Beats Earnings Estimates. Financial Chief Says It Can Do Any Deal It Wants. -- Barrons.com

16 lip 2025, 10:22 UTC

Earnings

Correct: Johnson & Johnson 2Q International Sales $10.2B >JNJ

16 lip 2025, 10:20 UTC

Earnings

Johnson & Johnson Beats Earnings Estimates. Financial Chief Says It Can Do Any Deal It Wants. -- Barrons.com

16 lip 2025, 10:20 UTC

Earnings

Johnson & Johnson Now Sees 2025 Adjusted Operational EPS $10.63-$10.73 Vs Prior Outlook $10.50-$10.70 >JNJ

16 lip 2025, 10:20 UTC

Earnings

Johnson & Johnson Raises 2025 View To Sales $93.2B-$93.6B Vs Prior Outlook $91B-$91.8B >JNJ

16 lip 2025, 10:20 UTC

Earnings

Johnson & Johnson Raises 2025 View To Adj EPS $10.80-Adj EPS $10.90 Vs Prior Outlook $10.50-$10.70 >JNJ

16 lip 2025, 10:20 UTC

Earnings

Johnson & Johnson: Increasing 2025 Operational Sales Growth to Be in Range of 4.5%-5% Vs Prior Range 3.3%-4.3% >JNJ

16 lip 2025, 10:20 UTC

Earnings

Johnson & Johnson Now Sees 2025 Operational Sales of $92.7B-$93.1B Vs Prior Outlook $91.6B-$92.4B>JNJ

16 lip 2025, 10:20 UTC

Earnings

Johnson & Johnson: Our Portfolio and Pipeline Position Us for Elevated Growth in Second Half of Year >JNJ

16 lip 2025, 10:20 UTC

Earnings

Johnson & Johnson Now Sees 2025 Adjusted Operational Sales Growth of 3.2%-3.7% Vs Prior Outlook 2%-3% >JNJ

16 lip 2025, 10:20 UTC

Earnings

Johnson & Johnson: 2Q MedTech Business Delivered Operational Sales Growth of 6.1%, Driven Primarily by Strength in Electrophysiology Products and Abiomed, Wound Closure Pdts and Improved Performance in Surgical Vision >JNJ

16 lip 2025, 10:20 UTC

Earnings

Johnson & Johnson 2Q Worldwide MedTech Sales $8.54B >JNJ

16 lip 2025, 10:20 UTC

Earnings

Johnson & Johnson: 2Q Innovative Medicine Operational Sales Growth Driven by Darzalex, Carvykti, Rybrevant, Lazcluze, Tremfya and Spravato >JNJ

16 lip 2025, 10:20 UTC

Earnings

Johnson & Johnson: 2Q Innovative Medicine Operational Sales Grew 3.8% With 13 Brands Growing Double Digits >JNJ

16 lip 2025, 10:20 UTC

Earnings

Johnson & Johnson 2Q International Sales $23.74B >JNJ

16 lip 2025, 10:20 UTC

Earnings

Johnson & Johnson 2Q Worldwide Innovative Medicine Sales $15.2B >JNJ

16 lip 2025, 10:20 UTC

Earnings

Johnson & Johnson 2Q U.S. Sales $13.54B >JNJ

16 lip 2025, 10:20 UTC

Earnings

Johnson & Johnson 2Q Sales $23.74B >JNJ

16 lip 2025, 10:20 UTC

Earnings

Johnson & Johnson 2Q EPS $2.29 >JNJ

16 lip 2025, 10:20 UTC

Earnings

Johnson & Johnson 2Q Adj EPS $2.77 >JNJ

16 lip 2025, 10:20 UTC

Earnings

Johnson & Johnson 2Q Orthopaedics Sales $2.3B >JNJ

16 lip 2025, 10:20 UTC

Earnings

Johnson & Johnson 2Q Orthopaedics Sales $2.31B >JNJ

16 lip 2025, 10:20 UTC

Earnings

Johnson & Johnson 2Q International Sales $10.2B >JNJ

16 lip 2025, 10:20 UTC

Earnings

Johnson & Johnson 2Q Worldwide Innovative Medicine Sales $15.2B >JNJ

Peer Comparison

Price change

Johnson and Johnson Forecast

Price Target

By TipRanks

4.29% upside

12 Months Forecast

Average 176.35 USD  4.29%

High 190 USD

Low 160 USD

Based on 19 Wall Street analysts offering 12 month price targets forJohnson and Johnson - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

19 ratings

9

Buy

10

Hold

0

Sell

Technical Score

By Trading Central

154.93 / 155.895Support & Resistance

Short Term

Bullish Evidence

Intermediate Term

Weak Bullish Evidence

Long Term

Bearish Evidence

Sentiment

By Acuity

48 / 375 Ranking in Healthcare

News Sentiment

Very Strong Bullish Evidence

Volatility

Below average

News Volume (RCV)

Above average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Johnson and Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. Its MedTech segment provides Interventional Solutions, including electrophysiology products to treat heart rhythm disorders; the heart recovery portfolio, which includes technologies to treat severe coronary artery disease requiring high-risk PCI or AMI cardiogenic shock; and neurovascular care that treats hemorrhagic and ischemic stroke. this segment also offers an orthopaedics portfolio that includes products and enabling technologies that support hips, knees, trauma, spine, sports, and other; surgery portfolios comprising advanced and general surgery technologies, as well as solutions for breast aesthetics, ear, nose, and throat procedures; contact lenses under the ACUVUE Brand; and TECNIS intraocular lenses for cataract surgery. It distributes its products to wholesalers, hospitals, and retailers, as well as physicians, nurses, hospitals, eye care professionals, and clinics. The company has a collaboration agreement with Stand Up To Cancer for research testing a combination of teclistamab and daratumumab to treat a rare disease AL amyloidosis. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.